Reappraisal of guidelines on hypertension management

Czech version

Authors: J. Špinar ¹; M. Souček ²
Authors‘ workplace: Interní kardiologická klinika Lékařské fakulty MU a FN Brno, pracoviště Bohunice, přednosta prof. MU Dr. Jindřich Špinar, CSc., FESC, 2II. interní klinika Lékařské fakulty MU a FN u sv. Anny Brno, přednosta prof. MU Dr. Miroslav Souček, CSc. ¹
Published in: Vnitř Lék 2010; 56(2): 157-161
Category: Letters to Editor

Overview

We present the core information from the “Reappraisal of European Guidelines on Hypertension Management”, an official document of the European Society of Hypertension updating the current guidelines of 2007 based on the new knowledge that became available over the last two years. The division of antihypertensive agents into 5 main groups remains unchanged. The key discussion is about whether the treatment of hypertension in high-risk patients should be initiated already at high normal blood pressure and whether the target value should be 130 mm Hg and less. Both objectives are just speculative at present as they have not been confirmed in a large clinical study. Thanks to the HYVET study we have more evidence for the benefits of hypertension therapy in older patients. Substantial part of the document focuses on combination therapy; the most encouraged combination is an ACE inhibitor + Ca blocker, or, alternatively, an ACE inhibitor or AII antagonist + diuretic. The beta-blocker + diuretic and ACE inhibitor + AII antagonist combinations are not recommended. Statins should be included in the therapy of all patients with hypertension, antiaggregation as a secondary prevention.

Key words:
hypertension – antihypertensives – combination therapy – high risk patient

Sources

1. Mancia G, Laurent S, Agabiti- Rosei L et al. Reappraisal of European guidelines on hypertension management: a European Society of hypertension Task Force document. J Hypertens 2009; 27: 2121– 2158.

2. Task Force Members 2007. Guidelines for the management of arterial hypertension. J Hypertens 2007; 25: 1105– 1187.

3. Widimský J. jr, Cífková R, Špinar J et al. Doporučení diagnostických a léčebných postupů arteriální hypertenze – verze 2007. Doporučení České společnosti pro hypertenzi. Cor Vasa 2008; 1: K3– 23.

4. Widimský J. jr, Cífková R, Špinar J et al. Doporučení diagnostických a léčebných postupů arteriální hypertenze verze 2007. Doporučení České společnosti pro hypertenzi. Vnitř Lék 2008; 1: 101– 118.

5. Widimský J. Komentář k přehodnocení evropských doporučení léčby arteriální hypertenze. Cor Vasa 2010; 52: v tisku.

6. Verdechia P, Angeli F, Cavalini C et al. The voltage of R wave in lead aVL improves risk stratification in hypertensive patients without ECG left ventricular hypertrophy. J Hypertens 2009; 27: 1697– 1704.

7. Sebestedt T, Jepensen J, Hansen TW et al. Which markers of subclinical organ damage to measure in individuals with high normal blood pressure. J Hypertens 2009; 27: 1165– 1171.

8. Inoue M, Maeda R, Kawakarni H. Aortic pulse walv velocity predict cardiovascular mortality in middle- aged and elederly Japanese men. Circ J 2009; 72: 549– 553.

9. Sleight P, Redon J, Verdechia P et al. Prognostic value of blood pressure in patients with high vascular risk in the Ongoing Telmisartan alone and in combination with Ramipril Global Endpoin Trial study. J Hypertens 2009; 27 (Suppl 4): 16.

10. Hypertension: management of hypertension in adults in primary care NCI/ BHS; 2006. www.nice.org.uk/ CG034.

11. Law MR, Moriis JK, Wald NU. Use of blood presure lowering drugs in the prevention of cardiovascular diseases: meta‑analysis of 147 randomised trials in the content of expectation from prospective epidemiological studies. BMJ 2009; 338: 1665– 1683.

12. Jamerson K, Weber MA, Bakris GL et al. Benazepril plus amlodipin or hydrochlorothiazide for hypertension in high risk patients. N Engl J Med 2008; 359: 2417– 2428.

13. Yusuf S, Teo KK, Pogue J et al. Telmisartan, ramipril or both in patients at high risk for vascular events. N Engl J Med 2008; 358: 1547– 1559.

14. Dahlof B, Sever PS, Poulter NR et al. Prevention of cardiovascular events with an antihypertensive regiment of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazidine as reguired. Lancet 2005; 366: 895– 906.

15. Wald DS, Law M, Moris JK et al. Combination therapy versus monotherapy in reducing blood pressure: meta‑analysis on 11 000 participants in 42 trials. Am J Med 2009; 122: 290– 300.

16. Blood presure lowering trialist colaboration: Effect of different regimens to lower blood pressure on major cardiovascular events in older and younger adults: meta‑analysis of randomised trials. BMJ 2008; 238: 1121– 1128.

17. Mann JG, Schmieder RE, Dyal L et al. Effect of telmisartan on renal outcomes: a randomised trial. Ann Intern Med 2009; 151: 1– 10.

18. Peters R, Beckett N, Forrete F et al. Incident dementia and blood pressure lowering in the HYpertensiuon in Very Elderly Trial cognitive function assement. Lance Neurol 2008; 7: 683– 689.

19. GISSI‑ AF investigators: Valsartan for prevention of recurrent atrial fibrillation. N Engl J Med 2009; 360: 1606– 1617.

20. Nasr IA, Bouzamondo A Hulot JS et al. Prevention of atrial fibrillation onset by beta blocker treatment in heart failure: a meta analysis. Eur Heart J 2008; 29: 2669– 2680.

21. Indian Polycap Study (TIPS): Effects of polypill (polycap) on risk factors in middle‑ aged individuals without cardiovascular disease (TIPS): a phase II double blind randomised trial. Lancet 2009; 373: 1765– 1772.